ASCO 2020 Discussion On Lung Cancer: Finding And Recent Drug Approvals

With more than a million cases per year in India, lung cancer is a shared cancer type. Earlier it was believed that only smokers were at higher risk of developing this. However, data from several years shows that this cancer type also affects individuals who have never smoked. As such, a Cancer specialist in Delhi NCR and the rest of the world strives to find an effective diagnosis and treatment methods. For this purpose, oncologists have conferences and discussions about the latest finding.

ASCO lung cancer conference: An Introduction

The American Society of Clinical Oncology (ASCO) hosts a conference for oncology professionals, industry reps, patients advocates, and media outlets every year. A multidisciplinary program aims to unite the efforts of hundreds towards progressing in the treatment and diagnosis of cancer. During the conference, oncologists and researches share their findings, observations, and views on cancer treatment. With the current pandemic situation, the latest ASCO meeting on lung cancer treatment, conducted in May of 2020 was virtual and discussed recent approvals of drugs that lung cancer treatment doctor can use to treat their patients.

Lung cancer treatment update 2020 in brief

The virtual conference on treatment options for lung cancer patients saw several oncologists within the ASCO discussing new targeted therapies and drugs for treating patients. The panel discussed medicines and cures for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) that can change the way an oncologist in Noida treats his (or her) patients. The panel cancer doctors also discussed the 35% risk of COVID-19 infection on lung cancer patients treated with chemotherapy. Several ongoing trials like AURA3 and ORIENT11 were also discussed during the latest ASCO meeting on lung cancer treatment.

Hopeful treatment options for NSCLC patients

Non-small cell lung cancer is one of two types of lung cancer that can affect both smokers and non-smokers. NSCLC constitutes for 80-85% of all lung cancer cases. The ASCO lung cancer treatment conference discussed treatment options for both early stage and advanced stage NSCLC cases.

Usually, early stage NSCLC patients undergo chemotherapy after surgery to prevent a recurrence. However, around 45% to 76% of the survivors have a recurrence within five years post treatment. A recent ADAURA trial studied the effects of patients who have been administered 0 following surgery. The result of this trial showed around 89% reduction of recurrence risk and was discussed during the ASCO conference. Once approved, osimertinib could turn the tide over the survival rates of treatment of lung cancer in Noida.

When it comes to the treatment of advanced stage NSCLC, the conference discussed the approval and ongoing trials of biomarker targeted therapy. Capmatinib recently got support for treating MET Exon 14 skipping mutations in lung cancer. On the other hand, amivantamab was in the phase 1 trial to treat EGFR Exon 20 insertion-mutated NSCLC. Similarly, trastuzumab deruxtecan is a promising drug undergoing phase 2 trials for treating HER2-mutated NSCLC. Aside from these, several more drugs that got FDA approval were also discussed during the ASCO conference. The best lung cancer doctor in Delhi NCR can use these therapies to treat NSCLC with driver mutations, an unmet need right now.

Yet another treatment option for NSCLC was also a topic of discussion in the conference: immunotherapy. Researchers are testing several immunotherapy combinations, some of which are currently in phase II and phase III trials. One such combination is combining an immune checkpoint inhibitor, tiragolumab, and antibody atezolizumab. This combination will be helpful for a cancer specialist in Delhi NCR to give patients first line treatment that boosts their immune system.

Positive horizons for SCLC treatment options

The small cell lung cancer (SCLC) is an aggressive type of lung cancer common in smokers, starting from the bronchi and spreads to the rest of the body. This cancer type constitutes around 10-15% of all lung cancer cases. The ASCO conference of lung cancer treatment discussed possible new therapies for limited stage SCLC and extensive stage SCLC.

The standard treatment for limited-stage SCLC is concurrent chemoradiotherapy. However, giving radiation and chemotherapy at the same time did not prevent a recurrence. Recent trial results show that a higher dose of radiation in the standard treatment will prevent a recurrence. However, much needs to be seen in that end. The conference discussed the CASPIAN trial’s positive results that combine durvalumab and chemotherapy for treating extensive stage SCLC.

Finding the best treatment of lung cancer in Noida

Lung cancer is one of the fatal cancer types. With limited treatment options, patients need a lung cancer treatment doctor that keeps up with the latest updates on treatments and drug approvals. With international accomplishments and numerous success stories, Dr. Manish Singhal is one of the best oncologists in Noida that patients can trust that he will be with them throughout their fight against lung cancer.

ALSO READ: Latest Breast Cancer updates from ASCO Annual Meeting 2020